ATAI

#2286
AtaiBeckley Inc. Common Stock
3.6900 USD
-3.40%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
3.6900
3.6900
年范围
3.3678
4.4000
日变化
-3.40%
每月变动
-6.58%
6个月变化
-6.58%
年变化
-6.58%
前一天收盘价
3.8200
Open
3.6900
Bid
3.6900
Ask
3.6930
Low
3.6900
High
3.6900
交易量
55
Open full chart

Financials

Overview 声明 Statistics
Quarterly Annual
  • Market Capitalization 802.9495 M
  • Employee 54
  • Founded 2018
  • CEO Florian Brand
  • Website www.ataibeckley.com
  • Headquarter Netherlands
  • FIGI BBG0107FR3K9
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-1.43
Price to sales ratio
691.6

AtaiBeckley Inc

atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways.

新闻